Interleukin-1β and anaphylatoxins exert a synergistic effect on NGF expression by astrocytes
- 6.5k Downloads
C3a and C5a anaphylatoxins are proinflammatory polypeptides released during complement activation. They exert their biological activities through interaction with two G protein-coupled receptors named C3aR and C5aR, respectively. In the brain, these receptors are expressed on glial cells, and some recent data have suggested that anaphylatoxins could mediate neuroprotection. In this study, we used RT-PCR and ribonuclease protection assays (RPA) to investigate the role of anaphylatoxins on neurotrophin expression by the human glioblastoma cell line T98G and by rat astrocytes. Our data show that for both cell types, anaphylatoxins upregulate expression of NGF mRNA. This response depended on a G protein-coupled pathway since pre-treatment of cells with pertussis toxin (PTX) completely blocked NGF mRNA increases. This effect was anaphylatoxin-specific since pre-incubation with anti-C3a or anti-C5aR antibodies abolished the effects of C3a and C5a, respectively. The regulation of NGF mRNA by anaphylatoxins was not accompanied by translation into protein expression, but there was a significant synergic effect of anaphylatoxins/IL-1b costimulation. Our demonstration of involvement of anaphylatoxins in the NGF release process by astrocytes suggests that C3a and C5a could modulate neuronal survival in the CNS.
KeywordsNerve Growth Factor T98G Cell RNase Protection Assay Nerve Growth Factor Level Nerve Growth Factor Expression
central nervous system, NGF: nerve growth factor
pertussis toxin, RPA: ribonuclease protection assay.
Injury in the CNS produces a multi-faceted, complex cascade of events that includes immunological changes such as activation of the complement system and generation of antibodies, release of pro-inflammatory cytokines and chemokines, and production of reactive oxygen species leading to oxidative stress. Activation of the complement (C) system leads to release of various fragments among which the anaphylatoxins, C3a and C5a, are two proinflammatory polypeptides. C3a and C5a, which are liberated through cleavage of C3 and C5 by C convertases, exert their biological activities by binding to two G protein-coupled receptors named C3aR and C5aR, respectively . There is evidence that C biosynthesis occurs in the CNS and all components of the C system can be synthesized locally by astrocytes, microglia and neurons . Complement functions to eliminate intruding pathogens. However, there is now considerable evidence that increased complement synthesis and uncontrolled complement activation in the CNS contribute to pathological changes in the brain. Intrathecal complement activation has been shown to occur in multiple sclerosis, Alzheimer's disease, bacterial meningitis, stroke and other brain diseases [3, 4]. Inflammatory reactions in these disorders are also associated with expression of pro-inflammatory cytokines, including IL-1β, TNF-α, IL-6, IFN-γ and IL-8. Excess expression of these cytokines can result in the destruction of the body's own cells, particularly neurons.
Several classes of neurons rely on neurotrophic factors, including nerve growth factor (NGF), for their survival and maintenance of function. Neurotrophins have many important physiological roles during and after CNS development . Moreover, in brain disorders such as Alzheimer's disease increasing levels of endogenous NGF may be beneficial [6, 7]. NGF is produced predominantly by neurons under normal physiological conditions; whereas astrocytes become the major site of NGF synthesis in the CNS during periods of rapid glial proliferation or after injury in the adult brain, [8, 9, 10, 11]. Previous studies have shown that NGF secretion from astrocytes is modulated by various factors including glial cell growth, neurotransmetters and cytokines [12, 13, 14]. IL-1β is one of the most potent stimulators of NGF secretion in cultured neonatal astrocytes [15, 16, 14]. In normal, healthy brain, expression of IL-1β and its mRNA are very low , but these increase markedly in response to local inflammation, injury, or disease states such as Alzheimer's disease and stroke [18, 19, 20, 21].
There is now growing evidence that complement, and more specifically the anaphylatoxins, could participate in neuroprotection in the brain [22, 23, 24]. To further examine the potential roles of C3a and C5a in the CNS, we examined the release of NGF by astrocytes upon stimulation with anaphylatoxins, which thus may participate to neuroprotection.
Materials and methods
Reagents, cytokines and antibodies
PTX, human recombinant C5a, and IL-1β were purchased from Sigma, St Quentin Fallavier, France. Anti-C3a monoclonal antibody (G10) and anti-C5aR antibody, used to block the effect of C3a and C5aR, respectively, have been characterized previously [25, 26].
Human C3a was generated by activation of C, and purified as previously described .
Multiple-Associated-Peptide (MAP)-C3a and (MAP)-C5a peptides, corresponding to the C-terminal part of the anaphylatoxins (amino acids correspond 64–77 for C3a and 61–74 for C5a, respectively), attached to a poly-lysine comb (eight peptidic monomers) were synthesized by solid phase synthesis (Applied Biosystem) and were purified by reverse phase HPLC. Sequences were ascertained by amino acid analysis. The concentrations of MAP peptides were calculated with the whole Molecular Mass of the MAP peptide.
The human glioblastoma cell line T98G was obtained from American Type Culture Collection (Rockville, MD, USA). These cells were screened routinely using a Mycoplasma Detection Kit (Boehringer Mannheim, Meylan, France) to ensure that they were mycoplasma free. Cells were grown in Ham's F12 culture medium (Biowhittaker, Emerainville, France) supplemented with 1% penicillin and streptomycin (Life Technologies, Cergy-Pontoise, France), and 10% heat-inactivated fetal calf serum (Life Technologies).
Primary astrocytes were prepared from brain of new-born rats and cultivated as previously described . All stimulations with anaphylatoxins or IL-1β were realized in medium without serum (Ultradoma, Biowhittaker). The astrocyte marker glial fibrillary acidic protein (GFAP) was detected by flow cytometry in 95–97% of these cells. CR3-positive cells were not detected in primary astrocyte cultures using the OX42 monoclonal antibody (ECACC, Sigma) and analysis by flow cytometry.
Total RNA was extracted from cells using a guanidium isothyocyanate method followed by ultracentrifugation onto a cesium chloride cushion. Total RNA (50 μg) was treated for 20 min at 37°C with 90 U of RQ-1 RNase- free DNase (Promega, Charbonnières, France) in 100 μl of buffer (40 mM Tris-HCl pH 8, 10 mM NaCl, 6 mM MgCl2 and 10 mM CaCl2) and 200 U of RNasin ribonuclease inhibitor (Promega) to remove all traces of contaminating genomic DNA.
Human NGF and glyceraldehyde 3-phosphate deshydrogenase (GAPDH) primers were chosen according to their cDNA sequences reported in EMBL Data Library under Accession Numbers X52599 and M33197. Their sequences from 5' to 3' were as followed: NGF sense [AGG TGC ATA GCG TAA TGT CC], NGF antisense [CCT TGA CAA AGG TGT GAG TC], GAPDH sense [TGC CAT CAA CGA CCC CTT CA] and GAPDH antisense [TGA CCT TGC CCA CAG CCT TG]. The theoretical size was 642 pb for NGF and 549 pb for GAPDH.
Reverse transcription was carried out for 60 min at 37°C in 30 μl (final volume) with 2 μg of total RNA, 20 U RNasin (Promega), 250 pmol random hexamer primers pd(N)6 (Pharmacia Biotech, Orsay, France), 1 mM dNTPs (Pharmacia), 5 mM DTT and 400 U Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV)-RT (Life Technologies) in the reaction buffer (250 mM Tris-HCl, 375 mM KCl, 15 mM MgCl2). The reaction mixture was then heated to inactivate the MMLV-RT. PCR was carried out with 5 μl of cDNA pool, in 50 μl final volume with 1.5 mM MgCl2, 200 μM de (dNTPs), 100 pmol of NGF primers and 2 U of Taq DNA polymerase (Life Technologies) in the reaction buffer (20 mM Tris-HCl, 0.1 mM d'EDTA, 1 mM DTT). The PCR steps used were: denaturation for 4 min at 94°C, 25 to 30 cycles [denaturation 94°C for 40 s, annealing at 57°C for 50 s and extension at 72°C for 90 s], and final elongation step at 72°C for 10 min. PCR was performed in a Hybaid Omnigene thermocycler (Schleicher and Schuell, Céra-labo, Ecqueville, France. The absence of contaminant DNA was routinely checked by RT-PCR on negative control samples in which either the RNA samples were replaced with sterile water, or the MMLV-RT was omitted. For semi-quantitative RT-PCR, PCR was realized with a GAPDH:NGF primers ratio of 1:75 and 1 μCi [33P]dATP (Redivue, Amersham, Les Ulis, France). Experiments were conducted in which total RNA was amplified with different cycle numbers for GAPDH and NGF primers to assure that RNA bands after amplification were detected within the linear part of the amplifying curves. Autoradiograms were analyzed using Lecphor image analyzer (Biocom, Les Ulis, France). Results are expressed as a ratio of the area of the band of interest to the mean of the area of the housekeeping gene band. The NGF mRNA value, from unstimulated cells, was set to one unit arbitrarily and values for the other samples were calculated relative to this.
Multiprobe RNase protection assay (RPA)
After total RNA isolation, RPA was performed using the RiboQuant Multiprobe RNase Protection Assay System (BD PharMingen, Le Pont de Claix, France), according to the manufacturer's instructions. Briefly, the provided rat neurotrophin template set (rNT-1) contained probes for six neurotrophins (NGF, brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), neurotrophin-3 (NT-3) and NT-4) and two housekeeping genes (GAPDH and L-32). To synthesize anti-sense cRNA, the probes were labeled with [32P]α UTP (800 Ci/mmol, 10 mCi/ml; Amersham) using a transcription kit according to the manufacturer's manual. Ten micrograms of each sample were used for hybridization with the anti-sense RNA probe at 56°C for 12–16 h, followed by digestion of free probe and unprotected ssRNA with RNase solution (RNase A plus RNase T1). The remaining dsRNA was then extracted in chloroform-isoamyl alcohol (50:1) and was precipitated with ethanol and separated on a 7 M urea/6% polyacrylamide gel. A part of the undigested probe was used as marker standard. After drying, the gel was placed in an exposure cassette with a phosphor screen for 48 h. Bands were detected by phosphorimaging using ImageQuant software (Molecular Dynamics). A standard curve plotted with the undigested probe markers was used to identify the bands of various genes in the experimental samples. Results are expressed as a ratio of the volume of the band of interest to the mean of the volumes of the bands for the housekeeping genes. The neurotrophin mRNA value, from unstimulated cells, was set to one unit arbitrarily and values for the other samples were calculated relative to this.
Enzyme-linked immunosorbent assay (ELISA)
Concentrations of NGF protein in culture supernatant samples were determined by a specific sensitive ELISA (sensitivity 15.6 pg/ml): NGF Emax Immunoassay System (Promega), according to manufacturer's instructions. The absorbance was measured at A450 nm with a plate reader (Labsystems iEMS Reader MF) and NGF content in the samples was determined by comparison with a NGF standard curve. The level of NGF in the culture supernatants was expressed as pg/ml per 106 cells.
Data are expressed as mean ± SEM. Statistical analysis was performed using Student's t test. Differences were considered statistically significant at p < 0.05.
C3a and C5a anaphylatoxins increase NGF mRNA expression in human glioblastoma cell line T98G
In a first approach, we studied NGF mRNA expression in the human glioblastoma cell line T98G. This cell line expresses C3a and C5a receptors [28, 29] and has been shown to respond to anaphylatoxin stimulations, inducing IL-6 mRNA expression .
Anaphylatoxin-upregulated NGF mRNA expression is dose-dependent and specific
T98G cells were stimulated with MAP-peptides or anaphylatoxins in a range of 10-13M to 10-7M. Total RNA was extracted after 4 h of stimulation and NGF mRNA expression was measured. From 10-10M to 10-8M, we observed a linear relationship between the NGF mRNA expression and the concentration of the different agonists, showing dose-dependent increases in NGF mRNA (data not shown). A significant response was obtained when concentrations reached 10-10 M for MAP-peptides and 10-9M for anaphylatoxins with comparable activities for C3a and C5a derivatives; the effect was maximum at 10-8 M for both agonist types. These concentrations ranges match those recorded in previous studies on astrocytes [30, 31].
MAP-C3a and MAP-C5a upregulate NGF mRNA expression by rat primary astrocytes
To confirm previous results obtained with T98G, we examined neurotrophin expression by rat primary astrocytes stimulated by MAP-C3a or MAP-C5a. Variation of neurotrophin expression was assessed by the sensitive RPA technique. In the same series of experiments, we determined NGF, BDNF, CNTF, GDNF, NT-3 and NT-4 mRNA expression.
Anaphylatoxin stimulation increased NGF secretion by T98G cell line
Synergistic effect of anaphylatoxins and IL-1 beta on NGF secretion
These experiments aimed at showing the potential role of anaphylatoxins to produce neurotrophins in order to protect neurons from injury. This hypothesis comes from the observation that C3a has neuroprotective effects against NMDA-induced neuronal death only in mixed cultures of neurons and astrocytes . We postulated that this indirect effect of C3a on neuroprotection could be due, at least in part, to neurotrophin release by astrocytes.
It is well established that complement is produced in the brain, that complement activation permits the release of the anaphylatoxins, C3a and C5a; and that these signal through their respective receptors, C3aR and C5aR, since stimulation of glial cells by anaphylatoxins can increase cytokine production [24, 30, 31]. The roles of anaphylatoxins on brain cells remain ill-characterized and they may have functional roles independent of their classical role as mediators of inflammation. Altought complement has been implicated as a mediator of neuroinflammation and neurodegeneration, as in Alzheimer's disease [35, 36], some inflammatory mediators, in particular the anaphylatoxins, are reported to have neuroprotective role.
In the present study, we sought to obtain further clues on the potential roles of C3a and C5a anaphylatoxins in neuroprotection by investigating the effects of C3a and C5a in parallel with their peptidic analogs, MAP-C3a and MAP-C5a on NGF release by astrocytes. Preliminary studies were performed by RT-PCR using the human T98G cell line. Our laboratory has previously shown that these cells express C3aR and C5aR, and using a cell line provided uswith homogenous material perfectly adapted for using RT-PCR technique. Thus, we observed that stimulation of T98G cells by anaphylatoxins induced increased expression of NGF mRNA. This upregulation was shown to be dose-dependent as NGF mRNA expression varied with the concentration of anaphylatoxins. Optimum concentrations (10-8 M) are in agreement with previous studies [30, 31]. Pre-treatment of cells with PTX completely blocked the effects of anaphylatoxinx and the MAP-peptides, suggestong that their effects were mediated through their specific receptors C3aR and C5aR. Pre-incubation with anti-C3a or anti-C5aR antibodies abolished the C3a- and C5a-induced NGF mRNA increase respectively, showing that the response was specific. Thus, the NGF mRNA increase acted via the anaphylatoxins/anaphylatoxin receptors and was not due to contaminants in anaphylatoxin preparations.
Analysis of NGF mRNA expression following anaphylatoxin stimulation was also studied using rat primary astrocytes analyzed by RPA. We showed that unstimulated rat astrocytes constitutively express NGF, BDNF and CNTF mRNA. Furthermore we observed a significant NGF mRNA increase after anaphylatoxin stimulations whereas BDNF and CNTF mRNA expression remained unchanged.
We consistently observed an increase in NGF concentation in cell supernatants following anaphylatoxin stimulation compared to unstimulated cells. It appeared that this effect was not statistically significant even for long incubation periods (48 h). In a previous study, we showed increased IL-8 mRNA expression  in response to anaphylatoxins, although this was not translated into secretion of cytokine. This IL-8 secretion was induced by co-stimulation of astrocytes with IL-1β and anaphylatoxins. A synergistic effect of IL-1β with TNF-α on NGF secretion by cultured rat astrocytes has been reported . Since IL-1β has no effect on C3aR and C5aR expression by T98G cells  we investigated the effects of anaphylatoxins/IL-1β costimulation on NGF release. We demonstrate here significant synergetic effects of IL-1β and anaphylatoxin-induced NGF-release. The significant increase in NGF secretion is likely to be a result of synergistic actions of IL-1β and anaphylatoxins since this dose of IL-1β had no effect on its own. It was established previously that anaphylatoxins do not induce IL-1-β expression  ruling out the possibility that NGF upregulation by anaphylatoxins is due to an indirect effect via IL-1-β.
Our data, showing that anaphylatoxins in synergy with IL-1β stimulate astrocyte NGF secretion, are consistent with the hypothesis that many cell types release complement proteins as a protective mechanism against threats to cell viability. A previous study showed that C3a anaphylatoxin significantly induces NGF mRNA and protein production in human microglia . This effect was obtained with a lower dose of C3a that that employed here. Moreover, in contrast to our results with astrocytes, C3a stimulation alone was sufficient to stimulate NGF secretion by microglia. In response to CNS injury, both microglia and astrocytes undergo structural and functional changes in a time-dependant manner. Microglia respond earlier than do astrocytes, and their response is often transient, whereas reactive astrocytes persist in their activated state. Thus, astrocytes may in a time-dependent manner supplant and continue the initial microglial NGF production. Anaphylatoxins may play a conditioning role in this process, allowing astrocytes to release neurotrophins in an inflammatory context.
In contrast to studies showing C5a-induced apoptosis in a human neuroblastoma cell line in vitro [38, 39], recent publications have implicated anaphylatoxins in neuroprotection [40, 22]. Thus, mice genetically deficient in complement component C5 are more susceptible to kainic acid excitotoxicity than are normal mice [41, 42]. Moreover, other studies have recently shown that C5a can directly protect neurons against glutamate neurotoxicity  and that C3a has protective effects against NMDA-induced neuronal death , suggesting involvement of anaphylatoxins in neuroprotection. Our findings elucidate a molecular basis for such anaphylatoxin-mediated neuroprotection, and fit well with the general concept that anaphylatoxins released locally are involved in tissue repair or remodelling .
Anne-Christine Jauneau was supported by a grant from Conseil Général de Haute-Normandie.
- 1.Ember JA, Jagels MA, Hugli TE: Characterization of complement anaphylatoxins and their biological responses. Edited by: Volanakis JE, Frank MM. 1998, The Human Complement System in Health and Disease, Marcel Dekker, New-York, 241-284.Google Scholar
- 11.Arendt T, Bruckner MK, Pagliusi S, Krell T: Degenerationof rat cholinergic basal forebrain neurons and reactive changes in nerve growth factor expression after chronic neurotoxic injury--I. Degeneration and plastic response of basal forebrain neurons. Neuroscience. 1995, 65: 633-645.CrossRefPubMedGoogle Scholar
- 29.Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M, Morgan BP: The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol. 1998, 160: 3543-3554.PubMedGoogle Scholar
- 41.Pasinetti GM, Tocco G, Sakhi S, Musleh WD, DeSimoni MG, Mascarucci P, Schreiber S, Baudry M, Finch CE: Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol Dis. 1996, 3: 197-204.CrossRefPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.